No Data
Johnson & Johnson (JNJ.US) monoclonal antibody therapy achieves Phase 3 clinical primary endpoints significantly delaying high-risk SMM progression.
The American Society of Hematology (ASH) released abstracts of some studies at its 2024 conference.
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Johnson & Johnson Analyst Ratings
Why Most Healthcare Stocks Are Falling With Trump's Win, With Some Exceptions
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $162
No Data
No Data
